ClinicalTrials.gg
CompletedNCT00520403Updated Oct 13, 2014Results posted

A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

A Phase 2 interventional study of bevacizumab [Avastin] and Interferon alfa-2a in Renal Cell Cancer, sponsored by Hoffmann-La Roche. Completed at 16 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-13.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing bevacizumab in Carcinoma, Renal Cell — 1 open to participants now, 3 under way, none of them phase 3. Bevacizumab · Carcinoma, Renal Cell.

Enrollment
32nd of 44
25 · median 46
Started
2007
with 4 others
Phase 2
25 of 44
1 open now
Registered
14th of 44
by date
Lead sponsor
5 of 44
Hoffmann-La Roche

Among the 44 studies testing bevacizumab in Carcinoma, Renal Cell, this one is the 32nd largest by enrollment, is one of 5 that started in 2007, is one of 25 in phase 2, and was the 14th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

1 of the 44 studies testing bevacizumab in Carcinoma, Renal Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing bevacizumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This single arm study will assess the efficacy and safety of Avastin in combination with interferon alfa-2a and vinblastine as first line treatment in patients with metastatic renal cell cancer. Patients will receive Avastin (15mg/kg iv) every 3 weeks, interferon alfa-2a 3 times weekly (3 Mio IU sc escalating to 18 Mio sc) and vinblastine (0.1mg/kg iv) every 3 weeks. The anticipated time on study treatment is until tumor progression, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Renal Cell Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • renal cell cancer of predominantly clear cell type;
  • >=1 .

Exclusion criteria

Exclusion Criteria:

  • prior treatment with chemotherapy, cytokine or tyrosine kinase inhibitor therapy for renal cell cancer;
  • ongoing or recent need for full therapeutic dose of anticoagulants or chronic daily treatment with aspirin (>325mg/day);
  • cardiovascular disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: Interferon alfa-2a · Drug: Vinblastine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Disease Progression or Death

    Disease progression was evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) using computed tomography (CT) scans (preferred method), magnetic resonance imaging (MRI) scans, X-ray, bone scans, or clinical examination.

    Time frame: Days 0, 91, 182, 273, 365, 456, and 547

  2. PFS - Time to Event

    PFS was defined as the time in days from the date of treatment start to the date of first documented disease progression or death. Disease progression was evaluated according to RECIST using CT scans (preferred method), MRI scans, X-ray, bone scans, or clinical examination. Median PFS was estimated using the Kaplan-Meier method

    Time frame: Days 0, 91, 182, 273, 365, 456, and 547

Secondary outcomes

  1. Percentage of Participants With Objective Response (OR)

    Percentage of participants with OR based on assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to RECIST.

    Time frame: Baseline and Cycles 3, 6, 9, 13, and 17

  2. Overall Survival (OS)

    OS was defined as the duration from treatment start to death from any cause. Overall survival was censored at the last contact for surviving participants and missing data points.

    Time frame: Baseline, Day 1 of every cycle to disease progression or death (up to Week 102)

07

Results

Posted Oct 13, 2014

Participant flow

Bevacizumab + IFN/Vinblastine
Participant flow — Bevacizumab + IFN/Vinblastine
MilestoneBevacizumab + Interferon Alfa-2a (IFN)/Vinblastine
Started25
Completed7
Not completed18
Withdrew: Radiological progression of cancer6
Withdrew: Adverse event4
Withdrew: Withdrawal of consent4
Withdrew: Death2
Withdrew: Discontinuation of study/background drug1
Withdrew: Protocol deviation affecting safety1
Bevacizumab Monotherapy
Participant flow — Bevacizumab Monotherapy
MilestoneBevacizumab + Interferon Alfa-2a (IFN)/Vinblastine
Started2
Completed0
Not completed2
Withdrew: Radiological progression of cancer1
Withdrew: Symptomatic progression of cancer1

Outcome measures

PrimaryPercentage of Participants With Disease Progression or Death

Disease progression was evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) using computed tomography (CT) scans (preferred method), magnetic resonance imaging (MRI) scans, X-ray, bone scans, or clinical examination.

Time frame:
Days 0, 91, 182, 273, 365, 456, and 547
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression or Death
percentage of participantsBevacizumab + IFN/Vinblastine
Percentage of Participants With Disease Progression or Death66.9
SecondaryPercentage of Participants With Objective Response (OR)

Percentage of participants with OR based on assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to RECIST.

Time frame:
Baseline and Cycles 3, 6, 9, 13, and 17
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR)
percentage of participantsBevacizumab + IFN/Vinblastine
Week 9 (n=14)21.4
Week 18 (n=16)31.3
Week 27 (n=16)37.5
Week 39 (n=16)31.3
Week 51 (n=16)31.3
SecondaryOverall Survival (OS)

OS was defined as the duration from treatment start to death from any cause. Overall survival was censored at the last contact for surviving participants and missing data points.

Time frame:
Baseline, Day 1 of every cycle to disease progression or death (up to Week 102)
Reported as:
Median · weeks
Overall Survival (OS)
weeksBevacizumab + IFN/Vinblastine
Overall Survival (OS)NA (NA to NA)
PrimaryPFS - Time to Event

PFS was defined as the time in days from the date of treatment start to the date of first documented disease progression or death. Disease progression was evaluated according to RECIST using CT scans (preferred method), MRI scans, X-ray, bone scans, or clinical examination. Median PFS was estimated using the Kaplan-Meier method

Time frame:
Days 0, 91, 182, 273, 365, 456, and 547
Reported as:
Median · days
PFS - Time to Event
daysBevacizumab + IFN/Vinblastine
PFS - Time to Event274 ± 31.6

Adverse events

Collected over From treatment start to 28 days after treatment cessation in the regular treatment period only (Cycles 1 through 17; bevacizumab + IFN/vinblastine). Does not include AEs reported during bevacizumab monotherapy (Cycles 18 and beyond).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab + IFN/Vinblastine—8/25 (32%)22/25 (88%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventBevacizumab + IFN/Vinblastine
NeutropeniaBlood and lymphatic system disorders1/25
Abdominal PainGastrointestinal disorders1/25
NauseaGastrointestinal disorders1/25
VomitingGastrointestinal disorders1/25
Chest PainGeneral disorders1/25
General Physical Health DeteriorationGeneral disorders1/25
Injection Site ReactionGeneral disorders1/25
Systemic Inflammatory Response SyndromeGeneral disorders1/25
DehydrationMetabolism and nutrition disorders1/25
Cerebral HaemorrhageNervous system disorders1/25
Most frequent other events
Showing 10 of 80
Most frequent other events
EventBevacizumab + IFN/Vinblastine
FatigueGeneral disorders10/25
AnorexiaMetabolism and nutrition disorders10/25
ProteinuriaRenal and urinary disorders8/25
NauseaGastrointestinal disorders7/25
Influenza like illnessGeneral disorders6/25
HeadacheNervous system disorders6/25
EpistaxisRespiratory, thoracic and mediastinal disorders6/25
HypertensionVascular disorders6/25
ChillsGeneral disorders5/25
Mucosal inflammationGeneral disorders4/25

Baseline characteristics

Safety Population: included all participants, even those who withdrew from the study prematurely and who received at least 1 dose of bevacizumab and had a safety follow-up visit.

Age, Continuous
Age, Continuous(years)Bevacizumab + IFN/Vinblastine
Mean62.2 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab + IFN/Vinblastine
Female4
Male21
08

Study locations

16 sites
  • Berlin, 10117, Germany
  • Berlin, 10967, Germany
  • Bremen, 28277, Germany
  • Dessau, 06846, Germany
  • Erlangen, 91052, Germany
  • Frankfurt, 60596, Germany
  • Halle, 06097, Germany
  • Hannover, 30449, Germany
  • Jena, 07743, Germany
  • Kassel, 34125, Germany
  • Kiel, 24105, Germany
  • Leipzig, 04103, Germany
  • Magdeburg, 39120, Germany
  • Rehling, 86058, Germany
  • Stuttgart, 70174, Germany
  • Weiden, 92637, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2007
First posted
Aug 24, 2007
Start
Sep 2007
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Oct 13, 2014
Last update
Oct 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00520403
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 24, 2007
Start date
Sep 2007
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Oct 13, 2014
Last update
Oct 13, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Interferon alpha-2 · Vinblastine

Start the discussion